If you've been following developments in weight loss medicine, you're likely familiar with semaglutide tablets. The active ingredient is the same as the Wegovy injection, but instead of a weekly injection, you swallow a pill once a day.
This guide explains exactly what Wegovy Semaglutide Tablets are, how they differ from the injectable version and from other oral semaglutide products, what the phase 3 trial data shows, how the dosing works, and where things currently stand in the UK. It's intended for anyone weighing up their options or simply trying to understand a treatment that has attracted a great deal of attention.
What Are Wegovy Semaglutide Tablets?
Wegovy Semaglutide Tablets are a once-daily oral weight loss treatment containing semaglutide, the same active ingredient found in Wegovy. They're marketed under the name Wegovy Semaglutide Tablets (or the Wegovy pill) and are manufactured by Novo Nordisk, the Danish pharmaceutical company behind the original injectable Wegovy pen.
The key distinction from older oral semaglutide products is both the dose and the licensed indication. Semaglutide tablets for weight loss are formulated at a target dose of 25mg per day, which is significantly higher than Rybelsus, an earlier oral semaglutide product licensed only for type 2 diabetes at doses up to 14mg. The higher dose is necessary because oral absorption of semaglutide is inherently limited, and a much larger amount needs to be taken to achieve the blood levels required for meaningful weight loss.
Semaglutide tablets received approval from the US Food and Drug Administration (FDA) in December 2025 and launched in the United States in January 2026, making them the first oral GLP-1 receptor agonist licensed specifically for weight management in the world.1 In the UK, the product is currently under review by the Medicines and Healthcare products Regulatory Agency (MHRA), with a decision expected later in 2026.
How Do Wegovy Semaglutide Tablets Work?
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after eating, signalling to the brain that you're full, slowing the rate at which food leaves your stomach, and helping to regulate blood sugar by stimulating insulin release in response to glucose.
By mimicking the effect of this hormone at a therapeutic dose, semaglutide produces several effects that support weight loss:
- Appetite reduction - semaglutide acts on areas of the brain that regulate hunger and reward, reducing the urge to eat and the appeal of high-calorie foods
- Delayed gastric emptying - food leaves the stomach more slowly, prolonging the feeling of fullness after meals
- Blood sugar regulation - by stimulating insulin release when blood glucose rises, semaglutide helps prevent the spikes and crashes that can drive cravings
- Reduction in "food noise" - many people on semaglutide report a reduction in intrusive thoughts about eating and food, an effect that clinical researchers have noted but is still being studied
These mechanisms work together to make it easier to eat less without the persistent hunger that makes calorie restriction difficult to sustain long-term.
What Is SNAC and Why Does It Matter?
The reason semaglutide tablets require a fasting protocol, and the reason the dose is so much higher than the injection, comes down to a molecule called SNAC (sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]).
Semaglutide is a peptide, and peptides are normally broken down by stomach acid and digestive enzymes before they can be absorbed. Without protection, almost none of an oral semaglutide dose would reach the bloodstream. SNAC addresses this in two ways: it raises the local pH around the tablet in the stomach, protecting semaglutide from acid degradation, and it temporarily increases the permeability of the stomach lining, allowing semaglutide to pass through into systemic circulation.2
Even with SNAC, oral bioavailability is only around 1% compared with the subcutaneous injection. This is why the tablet dose (25mg) appears so much higher than the injection maintenance dose (2.4mg for standard Wegovy, 7.2mg for the higher-dose version). The higher dose compensates for the lower absorption rate so that therapeutic blood levels are achieved.
SNAC technology is also why the fasting requirement is non-negotiable. Food disrupts both the pH effect and the gastric permeability window that SNAC creates. Taking semaglutide tablets with or too soon after food substantially reduces absorption, potentially to a level where the treatment has little effect.
How Effective Are Wegovy Semaglutide Tablets for Weight Loss?
The key clinical evidence comes from the OASIS 4 trial, a 71-week phase 3 randomised controlled trial in which 307 adults without diabetes, with a BMI of 30 or above (or 27 or above with at least one weight-related health condition), were assigned to either oral semaglutide 25mg or placebo, alongside lifestyle intervention.3
The results were significant. In the treatment-adherent analysis, covering people who completed the full 64 weeks on treatment, oral semaglutide 25mg produced an average weight loss of 16.6%, compared with 2.7% for placebo. In the intention-to-treat analysis, which includes all participants regardless of whether they completed treatment, average weight loss was 13.6%, compared with 2.2% for placebo.3
To put those figures in practical terms: a person starting at 100kg who adhered fully to treatment would, on average, lose around 16.6kg over 64 weeks. Around one in three participants in the adherent group achieved at least 20% body weight loss.
Beyond weight reduction, the OASIS 4 trial also found improvements in blood sugar control, waist circumference, blood pressure, and other markers associated with cardiovascular and metabolic health. These improvements are consistent with the broader semaglutide evidence base, which now includes more than 37 million patient-years of global use.
Wegovy Semaglutide Tablets vs the Wegovy Injection
Both the Wegovy Semaglutide Tablet and the Wegovy injection contain the same active ingredient and work through the same mechanism. The differences are practical rather than pharmacological.
The injection is administered once weekly, at any time of day, with or without food, with no storage requirements beyond refrigeration. The tablet is taken once daily, on a completely empty stomach, with no more than 120ml of plain water, followed by a 30-minute fast. The injection reaches circulation more predictably because it bypasses the stomach entirely. The tablet is affected by anything that disrupts absorption conditions: food, other medications, even larger quantities of water.
In terms of efficacy, the injection has a modest advantage in average weight loss. The STEP 1 trial of injectable Wegovy 2.4mg found average weight loss of approximately 14.9% over 68 weeks.4 For the higher-dose 7.2mg injection, the STEP UP trial reported an average of 20.7% over 72 weeks.5 The OASIS 4 results for the tablet (16.6% adherent, 13.6% overall) sit in a comparable range to the standard 2.4mg injection, though the trials used different designs and can't be directly compared.
The most important practical advantage of the tablet is the removal of needles entirely. For people with injection anxiety, needle phobia, or needle-related conditions, the tablet offers access to semaglutide treatment that was previously unavailable in an oral format for weight management.
Are Wegovy Semaglutide Tablets the Same as Rybelsus?
No, and this distinction matters. Both Rybelsus and Wegovy Semaglutide Tablets contain oral semaglutide and both use SNAC technology, but they're separate products with different licensed indications, different dose ranges, and different approved uses in the UK.
Rybelsus is licensed in the UK for the treatment of type 2 diabetes. Its dose range is 3mg to 14mg per day. It is not licensed, and has not been clinically studied at adequate doses, for weight management in people without diabetes.
Wegovy Semaglutide Tablets are formulated specifically for weight management, at doses up to 25mg per day. This higher dose is necessary to achieve the blood levels of semaglutide needed for clinically meaningful weight loss. Rybelsus at its maximum 14mg dose wouldn't be expected to produce the same results.
The terms are sometimes used interchangeably online, but they aren't interchangeable clinically. Anyone seeking semaglutide for weight management should use the product specifically licensed and studied for that purpose, not Rybelsus repurposed off-label.
Dosage and How to Take Wegovy Semaglutide Tablets
Semaglutide tablets follow a gradual dose escalation schedule, starting at a low dose and increasing every 30 days. This titration approach is designed to allow the body to adjust to the medication, reducing the likelihood of gastrointestinal side effects during the early weeks. The approved schedule is:
- Days 1 to 30: 1.5mg once daily
- Days 31 to 60: 4mg once daily
- Days 61 to 90: 9mg once daily
- Day 91 onwards: 25mg once daily (maintenance dose)
The maintenance dose of 25mg is taken once daily for the duration of treatment. If the 25mg maintenance dose isn't well tolerated, the prescribing information notes that switching to the Wegovy 1.7mg injection is an option to discuss with a clinician.
Administration must be consistent to maintain absorption. The correct protocol is:
- Take the tablet first thing in the morning, before any food, drink, or other medication
- Use no more than 120ml (a small glass) of plain water
- Swallow the tablet whole. Do not crush, split, or chew it
- Wait at least 30 minutes before eating, drinking anything other than plain water, or taking any other oral medication
The 30-minute window isn't a guideline; it's a pharmacological requirement. Food within 30 minutes of the tablet reduces semaglutide absorption, potentially to a level where the dose has little therapeutic effect.
Side Effects of Wegovy Semaglutide Tablets
The side effect profile of semaglutide tablets is broadly similar to that of the injectable version, with gastrointestinal effects being the most common.
In the OASIS 4 trial, nausea was reported by 46.6% of people in the semaglutide group, compared with 18.6% in the placebo group. Vomiting affected 30.9% of those on semaglutide versus 5.9% on placebo.3 These rates appear higher than those seen with the injection, which may reflect the daily dosing pattern compared with once-weekly injections. In the STEP 1 injection trial, nausea was reported in around 44% of participants.4
Despite the frequency figures, side effects were described as generally mild to moderate in severity, and most resolved over time. Discontinuation due to adverse events occurred in 6.9% of the semaglutide group, compared with 5.9% in the placebo group, a small difference that suggests the side effect burden was manageable for the majority of participants.3
The most commonly reported side effects include:
- Nausea - very common; most frequent during dose escalation; usually improves at maintenance dose
- Vomiting - very common during early weeks; typically transient
- Diarrhoea - common; median duration around four days per episode
- Constipation - common; can persist longer than other gastrointestinal effects
- Abdominal pain - common
Eating smaller meals, avoiding fatty or spicy foods, and not lying down immediately after eating can help manage gastrointestinal side effects. Dose escalation should not be accelerated. If side effects are poorly tolerated at a given dose, remaining at that dose for longer before increasing is preferable to stopping treatment.
More serious but less common side effects include pancreatitis and gallbladder problems. Anyone experiencing severe abdominal pain, particularly pain that radiates to the back, should seek urgent medical advice.
Wegovy Semaglutide Tablets and the Contraceptive Pill
This is a common question, and the clinical evidence is more reassuring than many online sources suggest.
Semaglutide slows gastric emptying, and because of this there's a theoretical concern that it could affect how quickly oral contraceptives are absorbed. However, pharmacokinetic studies of both injectable semaglutide and oral semaglutide have investigated this directly and found no clinically meaningful reduction in contraceptive absorption. In a dedicated drug interaction study, co-administration of oral semaglutide with a combined oral contraceptive containing ethinylestradiol and levonorgestrel didn't affect the bioavailability of either hormone; the pharmacokinetic parameters remained within standard bioequivalence limits.6
The FDA prescribing information for Wegovy Semaglutide Tablets notes that semaglutide has the potential to impact the absorption of concomitantly administered oral medications because of its gastric emptying effect, and recommends monitoring for medications with a narrow therapeutic index. However, oral contraceptives aren't considered to fall in this category based on available evidence, and no dose adjustment is recommended.
If you have any specific concerns about interactions between semaglutide and your contraceptive method, speak to your GP or prescribing clinician. Weight loss itself can also affect fertility in some women, which is a separate consideration worth discussing with your doctor.
Are Wegovy Semaglutide Tablets Available in the UK?
As of mid-2026, semaglutide tablets aren't yet available in the UK. The MHRA is currently reviewing Novo Nordisk's application for marketing authorisation, with a regulatory decision expected in the second half of 2026. Once MHRA approval is granted, private prescription availability through regulated online pharmacies and clinics, including Pharmica, would follow.
NHS availability is expected to take longer. Following MHRA approval, NICE would need to complete its own health technology appraisal before the tablets could be made available through NHS prescription. This process typically takes six to twelve months, making NHS access more realistic from 2027.
In the meantime, semaglutide for weight loss is available in the UK as the Wegovy injectable pen, which is MHRA-approved and accessible through private prescription. You can sign up for availability updates on the Wegovy Semaglutide Tablet page.
Who Could Be Eligible for Wegovy Semaglutide Tablets?
The FDA-approved indication for Wegovy Semaglutide Tablets mirrors that of the injection. In the United States, the tablet is licensed for adults with a BMI of 30 or above, or adults with a BMI of 27 or above with at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetes.
UK eligibility criteria will depend on the terms of the MHRA marketing authorisation when granted, but are expected to follow a similar structure to the existing Wegovy injection criteria. A full clinical assessment is required before any semaglutide treatment is started.
Semaglutide tablets are contraindicated in people with a personal or family history of medullary thyroid carcinoma, or those with Multiple Endocrine Neoplasia syndrome type 2. They are also not recommended during pregnancy or breastfeeding.
Existing options for weight management available now through Pharmica include Wegovy injectable pens, Mounjaro (tirzepatide), and Orlistat.
When to Seek Further Advice
Contact your GP or prescribing clinician if you:
- Experience severe or persistent abdominal pain, particularly pain radiating to the back
- Develop signs of pancreatitis: sudden severe upper abdominal pain alongside nausea and vomiting
- Notice significant changes in your heart rate (palpitations or a rapid resting pulse)
- Develop symptoms of gallbladder disease: upper right abdominal pain, especially after eating fatty foods
- Are experiencing side effects that make it difficult to continue treatment
- Are unsure whether semaglutide tablets interact with other medications you're taking, including contraceptives
Frequently Asked Questions
What are Wegovy Semaglutide Tablets?
Wegovy Semaglutide Tablets are a once-daily oral weight loss treatment containing semaglutide, the same active ingredient as the Wegovy injection. They're manufactured by Novo Nordisk and represent the first oral GLP-1 receptor agonist licensed specifically for weight management. The tablet is taken once a day on an empty stomach and works in the same way as the injection: by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and help you feel fuller for longer.
Do Wegovy Semaglutide Tablets work for weight loss?
Yes, the clinical evidence is strong. In the phase 3 OASIS 4 trial, adults taking oral semaglutide 25mg daily lost an average of 13.6% of their body weight over 64 weeks, rising to 16.6% in those who completed the full course of treatment. Around one in three participants in the adherent group achieved at least 20% body weight loss. These results are broadly comparable to the standard 2.4mg Wegovy injection, making Wegovy Semaglutide Tablets one of the most effective oral weight loss treatments studied to date.
Are Wegovy Semaglutide Tablets as effective as the injection?
Broadly yes, though the injection has a modest advantage in average weight loss figures. The OASIS 4 trial found 16.6% average weight loss with the tablet (in adherent patients), while the STEP 1 trial of the 2.4mg Wegovy injection showed 14.9% and the higher-dose 7.2mg injection achieved 20.7%. However, the trials used different protocols and can't be directly compared. The tablet's real advantage is practical: it removes needles, cold-chain storage, and injection anxiety entirely, making semaglutide treatment accessible to more people.
When will Wegovy Semaglutide Tablets be available in the UK?
Wegovy Semaglutide Tablets aren't currently available in the UK. Novo Nordisk submitted the application to the MHRA in late 2025, and a regulatory decision is expected in the second half of 2026. Once the MHRA approves them, private prescription availability through regulated online pharmacies would follow shortly after. NHS access would require a further NICE health technology appraisal, making that more realistic from 2027. You can register for availability updates on the Wegovy Semaglutide Tablet page.
How do you take Wegovy Semaglutide Tablets?
Wegovy Semaglutide Tablets must be taken first thing in the morning, on a completely empty stomach, with no more than 120ml (roughly half a glass) of plain water. You then need to wait at least 30 minutes before eating, drinking anything other than water, or taking any other oral medication. The SNAC absorption technology in the tablet is disrupted by food or large volumes of liquid, which can significantly reduce how much semaglutide reaches your bloodstream. Swallow the tablet whole; don't crush, split, or chew it.
Can I take Wegovy Semaglutide Tablets at night instead of in the morning?
The approved protocol specifies taking the tablet first thing in the morning before any food or drink. This is primarily because the fasting requirement is easiest to achieve reliably on waking, and because it ensures consistent absorption conditions each day. Taking the tablet at night is technically possible only if you can guarantee a fully empty stomach, typically several hours after your last meal and with no food or drink until 30 minutes after the tablet. In practice, morning dosing is strongly recommended and the approach used in all clinical trials.
How long do Wegovy Semaglutide Tablets take to work?
Most people notice some reduction in appetite within the first few weeks, though meaningful weight loss typically becomes apparent over the first one to two months. The dose escalation schedule, which starts at 1.5mg and works up to the 25mg maintenance dose over around three months, means the full therapeutic effect builds gradually. In the OASIS 4 trial, weight loss continued to accumulate across the full 64-week treatment period. Results vary between individuals based on starting weight, dose adherence, and lifestyle changes alongside treatment.
How much will Wegovy Semaglutide Tablets cost in the UK?
UK pricing hasn't been confirmed yet; that will follow MHRA approval. As a reference point, Wegovy Semaglutide Tablets launched in the US in January 2026 with self-pay pricing of approximately $149 to $299 per month depending on dose, which converts to roughly £115 to £230 at current exchange rates. UK private prescription prices typically differ from US pricing, and will also include VAT. Based on the US launch and existing UK injection pricing, industry estimates suggest the tablet is likely to be priced similarly to the Wegovy injection, which currently starts from around £120 to £150 per month privately.
Is the Wegovy Semaglutide Tablet the same as Rybelsus or Ozempic?
All three contain semaglutide, but they're different products with different licensed uses. Rybelsus is an oral semaglutide tablet licensed in the UK for type 2 diabetes only, at doses up to 14mg, and it's not licensed or adequately dosed for weight management. Ozempic is an injectable semaglutide pen also licensed for type 2 diabetes. Wegovy Semaglutide Tablets are a higher-dose oral formulation (up to 25mg) specifically developed and licensed for weight management, and they're not yet available in the UK. Using Rybelsus off-label for weight loss isn't the same as using the properly dosed Wegovy Semaglutide Tablet.
Does the Wegovy Semaglutide Tablets affect the contraceptive pill?
Clinical studies suggest it doesn't. Although semaglutide slows gastric emptying, which in theory could affect how oral medications are absorbed, pharmacokinetic trials of both oral and injectable semaglutide found no clinically meaningful reduction in the absorption of ethinylestradiol or levonorgestrel, the hormones in most combined oral contraceptives. The FDA prescribing information notes a general potential for semaglutide to interact with oral medications, but oral contraceptives aren't flagged as requiring dose adjustment. If you have specific concerns, speak to your GP or prescribing clinician.
Can you take anti-sickness tablets with Wegovy Semaglutide Tablets?
It depends on the specific medication. Common over-the-counter options like cyclizine or promethazine are generally considered compatible with semaglutide, but because Wegovy Semaglutide Tablets slow gastric emptying, any oral medication taken within 30 minutes of the tablet may have reduced absorption. Anti-sickness medication should ideally be taken at least 30 minutes after the Wegovy Semaglutide Tablet. For prescription anti-emetics or if nausea is severe or persistent, speak to your prescribing clinician before self-treating, as they may also be able to adjust your dose escalation schedule to help.
References
- Novo Nordisk. FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults. Press release. December 2025. novo-pi.com
- Buckley ST, et al. Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018;10(467):eaar7047. doi:10.1126/scitranslmed.aar7047
- Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Wharton S, Freitas P, Hjelmesaeth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). The Lancet Diabetes & Endocrinology. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8
- Hausner H, et al. Effect of oral semaglutide on the pharmacokinetics of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2021;60(3):361-371. doi:10.1007/s40262-020-00976-x
This article is intended for informational purposes only and does not replace professional medical advice. Always read the patient information leaflet supplied with your medication and speak to a healthcare professional if you have specific concerns.